Your browser doesn't support javascript.
loading
Response to the Selective RET Inhibitor Selpercatinib (LOXO-292) in a Patient With RET Fusion-positive Atypical Lung Carcinoid.
Kander, Elizabeth M; Shah, Manisha H; Zhou, Ye; Goyal, Ashima; Palmer, Joshua D; Owen, Dwight H; Shilo, Konstantin; Patel, Gopal; Raval, Raju R; Gonzalez, Javier; Nguyen, Michele; Olek, Elizabeth; Kherani, Jennifer; Rothenberg, S Michael; Konda, Bhavana.
Afiliação
  • Kander EM; Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH.
  • Shah MH; Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH.
  • Zhou Y; Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH.
  • Goyal A; Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH.
  • Palmer JD; Department of Radiation Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH.
  • Owen DH; Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH.
  • Shilo K; Division of Surgical Pathology, Department of Pathology, The Ohio State University Comprehensive Cancer Center, Columbus, OH.
  • Patel G; Division of Surgical Pathology, Department of Pathology, The Ohio State University Comprehensive Cancer Center, Columbus, OH.
  • Raval RR; Department of Radiation Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH.
  • Gonzalez J; Division of Neuro-Oncology, Department of Neurology, The Ohio State University Comprehensive Cancer Center, Columbus, OH.
  • Nguyen M; Loxo Oncology, Inc, a whole owned subsidiary of Eli Lilly & Co, Stamford, CT.
  • Olek E; Loxo Oncology, Inc, a whole owned subsidiary of Eli Lilly & Co, Stamford, CT.
  • Kherani J; Loxo Oncology, Inc, a whole owned subsidiary of Eli Lilly & Co, Stamford, CT.
  • Rothenberg SM; Loxo Oncology, Inc, a whole owned subsidiary of Eli Lilly & Co, Stamford, CT.
  • Konda B; Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH. Electronic address: bhavana.konda@osumc.edu.
Clin Lung Cancer ; 22(3): e442-e445, 2021 05.
Article em En | MEDLINE | ID: mdl-32660930
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pirazóis / Piridinas / Tumor Carcinoide / Proteínas Proto-Oncogênicas c-ret / Neoplasias Pulmonares Limite: Female / Humans / Middle aged Idioma: En Revista: Clin Lung Cancer Assunto da revista: NEOPLASIAS Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pirazóis / Piridinas / Tumor Carcinoide / Proteínas Proto-Oncogênicas c-ret / Neoplasias Pulmonares Limite: Female / Humans / Middle aged Idioma: En Revista: Clin Lung Cancer Assunto da revista: NEOPLASIAS Ano de publicação: 2021 Tipo de documento: Article